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One reason antimicrobial-drug resistance has recently
become a concern is its economic impact. The Institute of
Medicine estimates the annual cost of infections caused by
antibiotic-resistant bacteria to be U.S.$4 to $5 million (1).
However, methods for measuring economic impact of
resistance are in their infancy, and the studies leave many
questions unanswered (2). In this review, I examine
perspectives from which economic impact of resistance is
important, assess available data about economic methods
used for evaluating economic effect, and suggest issues
important for these assessments, as well as approaches for
further study.
Economic Impact: Differing Viewpoints
Several viewpoints toward antimicrobial-drug resistance
and its impact include those of physicians, patients, health-
care businesses, the drug industry, and the public (Table 1).
Physicians
The view most considered in day-to-day medical care is
that of the practicing physician. Physicians focus on
individual patients and are motivated by professionalism
that demands they seek the absence of disease, most often in
persons who are ill when they visit a physician. Thus, the
main economic problems that resistance presents for
physicians are related to ineffective treatment (e.g.,
consequences arising from patient death, disease). From this
treatment perspective, a production model of the type
presented by Scott (3) would relate the existence of multiple
antimicrobial agents to likely effectiveness in curing a given
patient’s infection. To clinicians treating individual patients,
availability of more antimicrobial agents than needed would
be of little or no concern. However, clinicians would be
alarmed by absence of effective agents (the “postantibiotic
era” cited frequently since Cohen’s publication of that title [4]
in 1992). From this viewpoint, the economic impact of
diminishing effectiveness of a given drug or group of drugs
depends on the availability of other drugs.
Patients
Patients with infections are likely to have a view similar
to that of the physician (Table 1), except that their motivation
for participating in the treatment process is their own well-
being. Economic impact is also measured in terms of
consequences arising from illness and death, specifically the
added cost of treatment of a resistant organism, since patients
pay retail prices for drugs and services. Such charges are
assumed directly when patients pay their own bills or
absorbed indirectly when added costs of multiple drugs and
services result in increasing premiums for patients who have
health-care coverage.
Health-Care Businesses
Today, health-care system financial resources in the
United States are less frequently controlled by doctors and
nurses and more often by administrators, financial
managers, third-party payers, and politicians. These people
see reduced illness and death as a reasonable goal, but also
seek objective evidence that this goal is achieved with fiscal
efficiency (i.e., by the least expenditure of increasingly scarce
financial resources [5]). Antimicrobial drugs represent a way
to provide cost-effective care to patients who are part of a
defined population being served. The economic cost of
antimicrobial-drug resistance for health-care businesses is in
the measures they must take to preserve the effectiveness of
antimicrobial agents in the care group. These measures may
include costs for a series of different drugs and services, as
well as for personnel time, supplies, space, and equipment for
institutional programs to deal with antimicrobial-drug
resistance (e.g., pharmacy and therapeutics committees,
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Table 1. Perspectives of economic impact of antimicrobial-drug
resistancea
   Focus Outcome Time Motivation Approach
Physician Individual Health Short   Profes- Treatment
    sional-
    ism
Patient Individual Health Short   Health Treatment
Provider Care group Lower Short   Profit Cost
  cost   contain-
  ment
Industry Clients Sales Short,   Profit New drugs,
  long   viable
  old drugs
Public Population Health Long   Social Lower
    good   chance of
  resistance
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antimicrobial-drug use review, practice guidelines). The
benefit is decreased costs associated with care of patients
infected with resistant organisms. Antimicrobial-drug
resistance in other settings is of interest to the health
business professional only as it affects or has the potential to
affect the population receiving the health-care organization’s
services. From this perspective, health-care organizations
may be the easiest setting in which to measure the economic
impact of antimicrobial-drug resistance. Here, the analysis is
limited to specific antimicrobial drugs, and the impact on care
for a specific group of patients can be measured in terms of
costs to the specific business. In addition, the costs of
measures to preserve effective treatment can also be assessed
in relation to other costs.
Drug Industry
The focus for pharmaceutical firms and other groups
providing products for treatment and prevention of infectious
diseases (e.g., antimicrobial agents, products to stimulate
host defenses, vaccines) is similar to that of the health-care
business. This group is also motivated by profit and focuses on
potential clients; however, the clients of interest are the
potential users of their products--direct (patients) and
indirect (health-care systems, governments, and the like)--
rather than enrolled subscribers to a health plan. Product
sales are the desired outcome, and a short-term view of sales
is part of their outlook. However, industry must also take a
longer view of the subject and consider the impact of
resistance as potential for introduction and sale of new
products, necessitating a two-pronged approach. On the one
hand, firms wish to maintain the life of their current
antimicrobial products, a goal threatened by new patterns of
antimicrobial-drug resistance. On the other hand, resistance
may make obsolete a competitor’s product, opening up the
field for a product that may have been less marketable
because it cost more or was less safe or effective. In addition,
resistance to drugs may produce a niche for a new
antimicrobial agent.
Public (“Societal View”)
A final view to be considered is that of public health or the
public good. This societal perspective, fueled by the goal of
social good, encompasses entire populations, whether of
towns, cities, countries, and even the entire world. As the goal
here is to maximize health for the whole population, the time
frame is usually long term. Since antimicrobial drugs
enhance both prevention and treatment of infections, society
considers them a valuable resource. As resistance diminishes
this resource, a societal goal would be to minimize resistance
and therefore the forces that produce resistance.
In the jargon of economics, antimicrobial agents are a
scarce resource, that is, one in which consumption (current
use) decreases its effectiveness (future value) (6). Any use of
antimicrobial agents enhances the likelihood of resistance.
From a societal viewpoint, then, appropriate use of
antimicrobial drugs for treatment and prevention of infection
would lead to an appropriate or acceptable decrease in the
value of antimicrobial effectiveness. Conversely, overuse or
misuse of antimicrobial drugs would create an inappropriate
decrease in these resources. When treating one person leads
to decreased effectiveness in treating the next person
receiving the drug, society is affected adversely. This impact
is often ignored because the short-term outcome and cost of
drugs (for example, for perioperative prophylaxis) can be
measured readily, and the detrimental effect on long-term
usefulness is unquantified for most situations (7).
Whose Perspective?
The economic costs and benefits of programs to preserve
antimicrobial effectiveness must be interpreted in the context
of these differing points of view. In any single study, it is
essential to keep the same perspective, whichever it may be.
Analyses that mix the different points of view in assessment
tend to confuse rather than clarify the problem and its extent.
For example, the business viewpoint might value loss of
effectiveness of a cheap antimicrobial agent as important
when it leads to use of a more expensive agent for patient care.
In contrast, the medical viewpoint might find loss of
effectiveness of the cheaper drug of little consequence as long
as other effective drugs are available.
Similarly, the value of antimicrobial effectiveness might
differ from an economic viewpoint rather than the medical
one. For example, from a public health perspective, the use of
antimicrobial agents to promote growth in animals would be
evaluated by comparing the relative benefit to food production
against the potential for decreasing the effectiveness of
prevention and treatment of infections in humans. In
contrast, the physician’s perspective would evaluate the use
of antimicrobial agents in animals in terms of its impact on
the effectiveness of specific medical therapeutic agents.
A third example of varying perspectives is the use of
measures to control the physician’s choice of antimicrobial
agents. This step may make great sense to hospital or other
health-care administrators when it is likely to produce more
efficient use of resources. Yet the control measures might be
seen as having no value by clinicians who are willing to use
any and all resources to cure their patients.
Assessing the Economic Impact of Resistance
Net economic impact of resistance can be viewed as the
attributable cost of treatment of an infection due to a resistant
isolate (“treatment cost”) minus the cost of preventing such
infections (“prevention cost”). Cost analysis should include
consideration of all resources affected by illness or
intervention (8). Economic impact of antimicrobial-drug
resistance includes a wide range of factors important to
various viewpoints (Table 2). The difference in this situation
is the added cost for each element associated with infection
with a resistant organism compared with the cost for the same
element if associated with infection caused by a susceptible
microbe (Table 2).
Costs for laboratory tests, radiologic studies, broncho-
scopies, or other diagnostic procedures are part of diagnostic
costs and primarily of concern to the health-care institution
when these costs cannot be passed on to the patient or an
insurer. The same is true of costs for purchase and
administration of antimicrobial drugs and other therapeutic
agents. Patients experience both direct costs of health care
and indirect costs (e.g., loss of productivity resulting in
reduction in income). Other types of indirect costs of
antimicrobial-drug resistance are costs to the drug industry
resulting from diminishing marketability of their drugs and
costs to businesses for loss of workers’ productive time. All
these factors are part of the economic impact of resistance.
Studies of the economic impact of resistance have not
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usually focused on hospital charges and length of stay,
features that are objective and relatively easy to collect
compared with other aspects of impact. Recent studies of
impact have also included estimates of increased hospital or
other institutional stay, incremental specific treatments, and
additional diagnostic tests needed for a patient infected with
a resistant organism compared with a patient infected with a
strain of the same organism that is drug susceptible (Table 3)
(9-23). Attempts have also been made to measure death and
illness associated with resistant infections. Although these
are objective indicators of economic impact, until recently it
was impractical to obtain this information on the small
patient groups studied at individual hospitals or other single
health-care settings. In addition, few studies have been
published on the impact of antimicrobial-drug resistance
outside health-care locations. Further attention is needed to
the community setting, where much of antimicrobial
treatment is given and received (24).
Generalizations from single-center studies are hindered
by differences in local practices. For example, some centers
experience delays in transferring patients with positive
cultures for vancomycin-resistant enterococci or methicillin-
resistant  Staphylococcus aureus (MRSA) from acute-care
centers to long-term care facilities (25). Estimates of
incremental increase in length of hospital stay for these
institutions might differ from those where such problems do
not exist. Thus, multicenter studies would be needed to obtain
data that could be used to generalize about regional or
national estimates of impact.
Determining the economic impact of antimicrobial-drug
resistance to a given drug may have several facets (26). The
relative benefit of being able to use a given drug in comparison
with alternatives when this drug is not available must be
assessed. Thus, to decide the worth of an antimicrobial drug,
several elements must be considered. The incremental cost of
treating the patient with alternative agents must be
assessed, often by studies in which costs for care of patients
infected with isolates resistant to a commonly used agent
Table 3. Examples of studies of economic impact of resistance
published in 1999-2000
     First author        Features
Year        (ref.) Study methods        measured
2000 Soriano (9) Case-control, Death, length of
  cohort   hospital stay
2000 Roghmann (10) Cohort Mortality rates at 7
  & 30 days, length of
  hospital stay, direct
  health-care costs
2000 Vanhems (11) Cohort Death
2000 Simor (12) Comparison of Incremental length
  cases with   of hospital stay
  arbitrary criteria
2000 Harthug (13) Case-control Death
2000 Bhavnani (14) Case-control Death
2000 Feikin (15) Cohort Death
2000 Garbutt (16) Retrospective Death
  cohort
1999 Carmeli (17) Cohort Death, length of
  hospital stay,
  hospital charges
1999 Rubin (18) Modeling, assump- Death, direct
  tion and extrapo-   medical costs
  lation from case
  reports
1999 Weingarten (19) Case-control Use of ventilators,
  length of hospital
  stay, duration and
  number of anti-
  microbial agents,
  hospital and
  pharmacy charges
1999 Gonzalez (20) Cohort Death
1999 Abramson (21) Case-control Length of hospital
  stay, attributable
  median total cost
Table 2. Elements of the economic impact of antimicrobial-drug resistance, by perspective affected
Element            Measurementa Perspective affected
Death [Costs associated withtreatment failure (R)] - [Costs associated with treatment failure (S)] Physician, patient, HCB
Illness [Costs associated with pain, suffering, inconvenience (R)] - [Costs associated with pain, Physician, patient
    suffering, inconvenience (S)]
Care cost [Charges for care (R)] - [Charges for care (S)] Patient
Care time [Time devoted to care (R)] - [Time devoted to care (S)] Physician, HCB
[Length of process (R)] - [Length of process (S)]b Patient, society
Diagnosis costs [Costs for diagnosis (R)] - [Costs for diagnosis (S)] HCB
Treatment costs [Costs for drugs (additional drugs and treatments, more expensive drugs (R)] - [Costs HCB
    for drugs (S)]
Diminished [Market for drug use (R)] - [Market for drug use (S)] Drug industry
  marketability
New markets [Market for new drug (S)] - [New market for new drug (R)] (replace current market Drug industry
    leader; replace inexpensive drug with more expensive drug; provide new product)
Impact on [Increased resistance (R)] - [Increased resistance (S)] Society
  non-treated
aR = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business.
bCosts associated with lack of routine functions during infection, including loss of work, quality of life for patient (includes both inpatient and
outpatient components); for society, reduction of useful function in workforce.289 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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(drug X) are compared with costs for care of patients with
isolates that are susceptible to drug X. A potential problem
with this type of comparison is that a uniform reference group
is not readily available. For example, a study may compare
costs for care of patients with susceptible isolates treated with
drug X to costs for patients infected with isolates resistant to
drug X who are then treated with one or more alternative
drugs (e.g., Y,Z), when choice of drug is left to the patient’s
physician. However, other factors (such as altered renal
function or a patient’s inability to take oral medications)
leading to use of drugs Y or Z to treat patients infected with
resistant organisms may also have led to treatment with one
of these drugs in patients infected with susceptible
organisms. Thus, costs must be evaluated carefully to
compare these two groups of patients and account for other
factors affecting therapy. Study design may also influence the
measured impact of resistance (27,28).
Current Situation
For these and other reasons, measurement of the
economic impact of resistance is imprecise and incomplete.
Neither methods for direct measurement nor appropriate
surrogate variables have been found for some important
features. Methods used have primarily focused on case-
control strategies, which have limitations (27).
Further work needed on this aspect of the question
includes defining optimal methods of measurement,
including more aspects of economic impact, and disclosing the
perspective from which the assessment is being made.
Measurement of impact of resistance on patients through
cost-utility analysis may be helpful as well (29).
Measuring Benefit of Programs
to Minimize Resistance
Steps to Minimize Antimicrobial-Drug
Resistance and Its Economic Impact
Several strategies and approaches have attempted to
deal with resistance (Table 4) (30,31). The term “control”
seems inappropriate because true control of antimicrobial-
resistant organisms and their effects seems biologically and
historically impossible. However, statements from profession-
al societies, independent review groups, and governmental
agencies stress several measures to minimize the detrimental
effects of resistance (32-35). These include professional
educational programs, enhanced microbiologic surveillance,
enhanced surveillance of patients, implementation of
infection control procedures, development of vaccines against
resistant organisms, and prudent use of antimicrobial agents
for treatment and prophylaxis. These measures can be
evaluated in terms of their success in reducing antimicrobial-
drug resistance and its associated costs (36). However, costs
associated with each of the strategies must also be included in
the calculation of overall economic impact (26). These costs
are more or less important, depending on the perspective from
which the analysis is being conducted. The few analyses of
this type conducted to date focus on costs of infection
control (37).
Developing New Antimicrobial Drugs
and Other Therapeutic Agents
The most obvious way to combat resistance is to develop
new antimicrobial agents (38). Several new combinations or
classes of antimicrobial agents now may prove valuable to
combat infections caused by resistant bacteria (39,40).
Nonantimicrobial means to combat resistant organisms
(e.g., development of vaccines) will also assume more
importance (41,42).
Economic impact here is primarily a concern for the
pharmaceutical industry and consists of the net difference
between costs associated with developing new agents and the
profit from sale of the agents when they are marketed.
Surveillance for Antimicrobial-Drug Resistance
Surveillance is vital to determining measures needed to
control antimicrobial-drug resistance (43). New, rapid
laboratory methods are becoming available to facilitate this
important effort. Surveillance methods produce expenses in
use of diagnostic testing (e.g., microbiologic cultures), and they
require additional time for infection control and laboratory
personnel, as well as patient care staff, to interact with infection
control personnel and implement surveillance programs.
Implementing Infection Control Measures
Approximately 30% to 40% of resistant infections arise
from cross-infection via hands of hospital personnel, 20% to
Table 4. Elements of the economic impact of measures to deal with antimicrobial drug resistance, by perspective affected
Element                                        Measurementa Perspective affected directly
Develop new antimicrobial agents [Costs associated with drug development] - [Profit resulting Drug industry, HCB,
    from new drug’s use]   patient, society
Conduct surveillance [Cost of surveillance for infected and colonized patients (R)] HCB
    - [Cost of surveillance for infected and colonized patients (S)]
Implement isolation [Costs associated with barrier isolation (R)] - [Costs HCW, visitor, patient, HCB
    associated with barrier isolation (S)]
Adapt lab procedures [Costs associated with testing (R)] - [Costs associated with HCB, patient, society
    testing (S)]
Educate about resistance [Costs associated with educational programs (staff, patients) (R)] HCW, patient, visitor, HCB
    - [Costs associated with educational programs (staff, patients) (S)]
Improve drug administration [Costs for programs to improve drug administration (R)] HCW, HCB
    - [Costs for programs to improve drug administration (S)]
Improve drug choice [Costs for programs to improve drug choice (R)] - [Costs for Prescribers, HCB
    programs to improve drug choice (S)]
aR = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business;
HCW = health-care workers.290 Emerging Infectious Diseases Vol. 7, No. 2, March–April 2001
Special Issue
25% from the selective antimicrobial pressure, 20% to 25%
from introduction of new pathogens, and 20% from other or
unknown pathways (44). Costs for control of cross-infection
include those for masks, gowns, gloves, antiseptics, and other
equipment needed for proper isolation precautions; increased
personnel time needed to implement isolation procedures; and
effort involved in teaching procedures to health-care personnel.
Adapting Laboratory Methods for Detecting
New Types of Antimicrobial-Drug Resistance
Emerging antimicrobial-drug resistance affects the
ability of the clinical microbiology laboratory to detect and
report resistance. Several new resistance mechanisms in
gram-positive and gram-negative bacterial organisms are
difficult to detect with usual laboratory methods. To counter
these problems, the National Committee for Clinical
Laboratory Standards (Villanova, Pennsylvania) and other
groups have developed new testing methods, as well as
guidelines and standards for testing resistant organisms (45).
Costs associated with these efforts are usually borne by the
health-care system, whether or not the tests are performed in-
house. Patients and society ultimately bear these costs,
depending on the mechanism by which the health-care system
is paid.
Educational Programs
Physicians, students, residents, nurses, pharmacists,
infection control and quality assurance personnel, adminis-
trative staff, and others are frequently part of the health-care
team. Making sure that awareness of the problem of
antimicrobial-drug resistance and how to deal with it are part
of the educational program or in-service education offerings is
a key part of obtaining support to minimize resistance. Costs
here result from the time needed to prepare and deliver
educational presentations and for attendees to participate;
these costs are primarily borne by the health-care system.
Optimizing Antimicrobial Agent Administration
The way that antimicrobial agents are prescribed is a
major risk determinant for resistance (46). Programs to
monitor and improve procedures for proper dosing, interval
of administration, duration of treatment, and monitoring
for adverse effects have been undertaken and recently
updated (47,48).
The economic impact relates to the time and efforts of
prescribers, pharmacists, drug delivery personnel, and
administrative staff who provide direct care to patients and
set policy in pharmacy and therapeutics committees. Thus,
health-care institutions are primarily affected by these
attempts to minimize antimicrobial-drug resistance. The
combination of measures must be individualized to the
particular organism-antimicrobial pair, health-care institu-
tion, and specific care setting, for at least two reasons (47).
First, the reservoir for important resistant organisms varies
dramatically. For some, like MRSA, the reservoir is now in
persons in some communities as well as in health-care
facilities (49). For others, such as gram-negative bacilli
containing extended-spectrum beta-lactamase enzymes,
acute-care hospitals (especially intensive care units) and
nursing homes are the main reservoir (50). Second, the modes
by which different organisms are spread differ. MRSA seems
closely linked to person-to-person spread, whereas gram-
negative nonfermenting bacilli are often spread through
contaminated liquids and respiratory therapy devices. Thus,
assessment of economic impact of measures to minimize
resistance depends on the specific measures that must be
introduced in a given institution or setting.
Influencing Drug Choice
Recent interest has focused on improving antimicrobial-
drug use by controlling the choice of antimicrobial agents by
individual prescribers. Some reported efforts attempt to limit
use of inappropriate agents by removing specific drugs from
the list of available agents in the formulary or restricting
them to certain specialists (51,52). Practice guidelines are a
means of achieving uniformity of antimicrobial-drug use that
have been applied to many areas in addition to that of
infectious diseases. Project ICARE (Intensive Care Antimi-
crobial Drug Resistance Epidemiology) is a cooperative
project of the National Nosocomial Infections System of the
Centers for Disease Control and Prevention and the Rollins
School of Public Health of Emory University. A 1998 survey of
47 hospitals participating in Project ICARE showed that
clinical practice guidelines were reported frequently (70% of
hospitals) among measures to improve prescribing practices
(53). Guidelines are particularly useful in reducing costs of
therapy and total costs of prescription, while maintaining
quality of care (54). The question is whether these efforts can
reduce prevalence of antimicrobial-drug resistance; major
successes have been noted in recent studies, both in the
community and hospital (54).
Status of Methods and Results
Measurement of the economic impact of strategies to
minimize resistance is imprecise and incomplete (55). Some
information is available about the impact of these measures
on drug cost and length of hospital stay, number of diagnostic
tests, and number of therapeutic drugs used. Further work
needed includes designation or identification of optimal
methods for measurement, inclusion of more aspects of
economic impact, and carefully defining the perspective from
which the assessment is being made.
Conclusions
Determining the true economic impact of antimicrobial-
drug resistance is a challenge because so many variables and
perspectives are involved. Better methods are needed to
assess the practical implications for those from all
perspectives, whether prescriber, patient, health-care
business, pharmaceutical company, or the public. Because
studies completed to date have been hampered by their small
size and lack of uniformity, validity of the information
provided is unclear and extrapolating the studies to regional
or national or international levels is questionable.
Population-based studies of the true impact of resistance
would require large multicenter study groups and would be
valuable to help address the different perspectives. Relevant
studies will require sufficient size to describe baseline
antimicrobial-drug resistance, deal with limits of random
variation, and control for variables. Multicenter study groups
will likely have to be assembled to provide enough
observations, as well as sufficient resources. Only when this is
done can there be adequate exploration of the true magnitude
of the economic impact of antimicrobial-drug resistance.
The economic impact of antimicrobial-drug resistance
deserves more attention from government and professional291 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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societies. Neither the summary of the Report by the American
Society for Microbiology Task Force on Antibiotic Resistance
nor the National Coalition on Antibiotic Resistance mentions
this as an important area for study or as a concern for health
care (32,56). A draft public health action plan to combat
antimicrobial-drug resistance published by the federal
Interagency Task Force on Antimicrobial Drug Resistance
notes that costs of treating resistant infections place a
substantial burden on society and mentions the impact of in-
hospital cost of six common kinds of resistant bacteria (57).
As the U.S. health-care system has evolved into a
business in the past decade, administrators concerned with
cost and benefit have become important decision makers.
Thus, economic arguments are needed to convince health-
system administrators that antimicrobial-drug resistance is
a serious issue. The same considerations apply in other
countries as well (58). Lack of attention means that funding to
solve the problems is unlikely to be found. A change in
perception and action is needed to give this important issue of
the economic impact of antimicrobial-drug resistance the
priority it deserves.
Dr. McGowan is professor of epidemiology and of medicine (infec-
tious diseases) at Emory University. His research interests focus on
antimicrobial-drug resistance and its relation to antimicrobial-drug use.
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